WeVote
Log In

Bill

Bill

HB 136

Sickle cell disease; feasibility of Medicaid benefit and Medicaid Health Homes, report.

2026 Regular Session Introduced by David Reid

Virginia would study expanding Medicaid coverage and coordinated care programs for sickle cell disease patients and report feasibility findings to lawmakers.

Left in Committee Communications, Technology and Innovation
0
WeVote Research Nonpartisan
Bill Summary · HB 136

Legislative bill overview

HB 136 directs Virginia to study the feasibility of expanding Medicaid coverage specifically for sickle cell disease treatment and establishing specialized "Health Homes" (coordinated care programs) for sickle cell patients. The bill requires a report back to the legislature detailing costs, implementation barriers, and recommendations.

Why is this important

Sickle cell disease is a severe genetic blood disorder disproportionately affecting Black Americans and causing significant morbidity and mortality. Expanding Medicaid coverage and care coordination could improve health outcomes and reduce emergency department utilization, though it requires understanding Virginia's fiscal capacity and current coverage gaps.

Potential points of contention

  • Cost concerns: Determining whether specialized Medicaid benefits and Health Homes are fiscally sustainable given state budget constraints, particularly as Medicaid already covers many sickle cell treatments
  • Scope of coverage: Debate over which specific sickle cell treatments or services warrant dedicated Medicaid funding versus existing general coverage
  • Program design: Questions about whether Health Homes (care coordination) should be disease-specific or part of broader Medicaid reform affecting multiple chronic conditions

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.